Target intelligence / Profile preview

Aflatoxin B1 (AFB1)

Target
AFB1
Molecular classification
Other (Mycotoxin), Carcinogen, Secondary metabolite
01

Overview

Aflatoxin B1 is a naturally occurring mycotoxin produced predominantly by the fungi Aspergillus flavus and Aspergillus parasiticus[4][5]. It is a colorless to pale yellow crystalline compound fluorescing blue under UV light and is considered the most toxic and carcinogenic aflatoxin, with a strong link to hepatocellular carcinoma (liver cancer) in humans and animals[1][3][4]. Aflatoxin B1 contaminates numerous crops (especially grains and nuts) in warm and humid climates, posing a major threat to food safety and public health worldwide. It is not a receptor, enzyme, transporter, or other classical drug/biological target, but rather itself a toxic small molecule of concern for poisoning and cancer risk[4][5][6].

Other names
Aflatoxin BAfB1AFB1afb1AFBIalflatoxinHSDB 3453NSC 529592
02

Mechanism of action

Drugs do not act “on” Aflatoxin B1 as a therapeutic target; some therapies may: - Bind or degrade Aflatoxin B1 to reduce toxicity - Enhance its metabolic detoxification via hepatic enzymes (e.g., glutathione S-transferases) - Prevent its absorption in the gut using enterosorbents such as activated charcoal or cholestyramine

03

Biological functions

Other (Natural toxin produced by Aspergillus flavus and Aspergillus parasiticus)Inhibition of biological macromolecules in host cells (e.g., DNA, RNA, protein synthesis via covalent adduct formation)Inducer of mutagenesis, carcinogenesis, and cytotoxicity[4][5][6]
04

Disease associations

Cancer (potent carcinogen, particularly hepatocellular carcinoma/liver cancer)Other (acute and chronic aflatoxicosis, toxic liver injury)
05

Safety considerations

Highly carcinogenic to humans and animals (Group 1, IARC classification)Potent hepatotoxinCan cause acute and chronic aflatoxicosis (liver failure, immunosuppression)Extremely potent at very low dosesFood contamination concern[4][5][6]
06

Biomarkers

Aflatoxin B1-albumin adducts (for human exposure monitoring)Aflatoxin B1-DNA adducts (for mutagenic effects and exposure)[4][5]

Beyond the preview

Go deeper on Aflatoxin B1 (AFB1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aflatoxin B1 (AFB1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call